GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cartesian Therapeutics Inc (NAS:RNAC) » Definitions » Market Cap

Cartesian Therapeutics (Cartesian Therapeutics) Market Cap : $373.91 Mil (As of Apr. 29, 2024)


View and export this data going back to 2016. Start your Free Trial

What is Cartesian Therapeutics Market Cap?

Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Cartesian Therapeutics's share price for the quarter that ended in Dec. 2023 was $20.682. Cartesian Therapeutics's Shares Outstanding (EOP) for the quarter that ended in Dec. 2023 was 5.40 Mil. Therefore, Cartesian Therapeutics's market cap for the quarter that ended in Dec. 2023 was $111.63 Mil.

Cartesian Therapeutics's quarterly market cap declined from Jun. 2023 ($171.84 Mil) to Sep. 2023 ($164.15 Mil) and declined from Sep. 2023 ($164.15 Mil) to Dec. 2023 ($111.63 Mil).

Cartesian Therapeutics's annual market cap declined from Dec. 2021 ($403.01 Mil) to Dec. 2022 ($172.94 Mil) and declined from Dec. 2022 ($172.94 Mil) to Dec. 2023 ($111.63 Mil).

Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Cartesian Therapeutics's Enterprise Value for Today is $307.95 Mil.


Cartesian Therapeutics Market Cap Historical Data

The historical data trend for Cartesian Therapeutics's Market Cap can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cartesian Therapeutics Market Cap Chart

Cartesian Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Market Cap
Get a 7-Day Free Trial Premium Member Only Premium Member Only 205.45 327.46 403.01 172.94 111.63

Cartesian Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Market Cap Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 172.94 213.26 171.84 164.15 111.63

Competitive Comparison of Cartesian Therapeutics's Market Cap

For the Biotechnology subindustry, Cartesian Therapeutics's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cartesian Therapeutics's Market Cap Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cartesian Therapeutics's Market Cap distribution charts can be found below:

* The bar in red indicates where Cartesian Therapeutics's Market Cap falls into.



Cartesian Therapeutics Market Cap Calculation

Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.

Cartesian Therapeutics's Market Cap for the fiscal year that ended in Dec. 2023 is calculated as

Market Cap (A: Dec. 2023 )=Share Price (A: Dec. 2023 )*Shares Outstanding (EOP) (A: Dec. 2023 )
=$20.682*5.39759
=$111.63

Cartesian Therapeutics's Market Cap for the quarter that ended in Dec. 2023 is calculated as

Market Cap (Q: Dec. 2023 )=Share Price (Q: Dec. 2023 )*Shares Outstanding (EOP) (Q: Dec. 2023 )
=$20.682*5.39759
=$111.63

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cartesian Therapeutics  (NAS:RNAC) Market Cap Explanation

Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the company’s debt. The real price you pay is the Enterprise Value.

Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.


Cartesian Therapeutics Market Cap Related Terms

Thank you for viewing the detailed overview of Cartesian Therapeutics's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.


Cartesian Therapeutics (Cartesian Therapeutics) Business Description

Traded in Other Exchanges
Address
65 Grove Street, Watertown, MA, USA, 02472
Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company. The company uses its ImmTOR immune tolerance platform, which is designed to give rise to antigen-specific immunity, mitigating unwanted immune responses. Its product pipeline includes MMA-101, SEL-212 for Chronic Severe Gout, SEL-313 for Ornithine Transcarbamylase Deficiency (OTC), and others.
Executives
Carsten Brunn director, officer: President & CEO C/O SELECTA BIOSCIENCES, INC., 480 ARSENAL WAY, WATERTOWN MA 02472
Peter G Traber officer: Chief Medical Officer 430 THAMER LANE, HOUSTON TX 77025
Takashi Kei Kishimoto officer: Chief Scientific Officer 480 ARSENAL ST., BUILDING ONE, WATERTOWN MA 02472
Lloyd P. Johnston officer: COO and SVP, R&D 480 ARSENAL ST., BUILDING ONE, WATERTOWN MA 02472
Blaine Davis officer: Chief Financial Officer C/O ARTARA THERAPEUTICS, INC., 1 LITTLE WEST 12TH STREET, NEW YORK NY 10014
Carrie Smith Cox director SCHERING-PLOUGH CORPORATION, 2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Timothy C Barabe director C/O ARQULE, INC., 1 WALL STREET, 6TH FLOOR, BURLINGTON MA 01803
Timothy A Springer director 36 WOODMAN ROAD, CHESTNUT HILL MA 02467
Kevin Tan officer: Chief Financial Officer 20 HICKORY ROAD, WELLESLEY MA 02482
Nishan M Desilva director 11119 NORTH TORREY PINES RD STE 200, LA JOLLA CA 92037
Ann K. Donohue officer: VP Finance C/O SELECTA BIOSCIENCES, INC., 480 ARSENAL WAY, BUILDING ONE, WATERTOWN MA 02472
Bradford D. Dahms officer: Chief Financial Officer C/O SELECTA BIOSCIENCES, INC., 480 ARSENAL WAY, WATERTOWN MA 02472
Goran Ando director
Scott Dunseth Myers director C/O CASCADIAN THERAPEUTICS, INC., 3101 WESTERN AVE., SUITE 600, SEATTLE WA 98121
Elona Esq. Kogan officer: General Counsel C/O SEER, INC., 3800 BRIDGE PARKWAY, SUITE 102, REDWOOD CITY CA 94065